Ocular Oncology, Day 6, online PG teaching initiative
Monday, 29th August'20

Topic : Lid Tumors
Speaker : Dr Swathi Kaliki, LVPEI, Hyderabad

Moderator : Dr Satyajit Sinha, AB Eye Institute, Patna and Dr. Vikas Khetan
Sankara Nethralaya, Chennai

Disclaimer: The presentation on the topics are copyrights to respective speakers and comes with restricted usage. The content cannot be used in parts or replicate or in any form for any purpose or commercial use.

The AB Eye Institute online PG teaching initiative is supported by Intas Pharmaceuticals Ltd with an objective to create robust online academic content on Ophthalmology therapies. We at Intas are thankful to all eminent speakers for sharing their views and experience and to AB eye institute for creating and making this online program as an indispensable program for Post Graduates. Happy Learning, Effective Learning

In this video, Melissa Wilson, PA-C, MPAS discusses BRAF/MEK inhibitors, the side effects associated with each drug, and how melanoma patients can manage the side effects.

This video discuss the ocular tumors including orbital tumors and eyelids tumors.

Presented by Theresa Medina, MD, University of Colorado Anschutz Medical Campus

Recent studies indicate that the composition of gut bacteria can influence the effectiveness of certain cancer immunotherapy drugs and that modulating the gut microbiome may expand the pool of patients benefiting from cancer immunotherapies. Checkpoint blockade therapy has been effective on several types of malignancies (e.g. melanoma, lung cancer, kidney cancer). However, the number of patients that do not respond, or only partially respond, to cancer immunotherapy is high. Recently, several human and mouse studies have shown that gut microbiome may be a significant determinant of the response to cancer immunotherapy. The gut microbiome may serve as a theranostic biomarker, by acting both as a useful prognostic biomarker and a target in cancer therapy. (NIH National Library)

Presented by,
Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Phase One Trials Program
The Angeles Clinic and Research Institute, Cedars Sinai Medical Care Foundation